Since 2011, ICIs targeting the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been approved for the treatment of metastatic melanoma and are currently used in clinical practice [11,12,13,14]. This evidence concerns the gene PDCD1 and metastatic melanoma.